Floatz logo

ZOPTARELIN DOXORUBICIN

Ovarian Cancer

AEterna Zentarisprotein_peptidePhase 2Dormant
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
29/ 100
Competitive Position
59/ 100

Competitive context

525 Active assets in the Ovarian Cancer cohort.

Asset / SponsorPhaseRating
Tisotumab Vedotin
Seagen Inc.
Phase 2BB
TIL
Inge Marie Svane
Phase 2BB
Olaparib
Shandong University
Phase 4BB
Carboplatin
Fudan University
Phase 4BB
Irinotecan
ARCAGY/ GINECO GROUP
Phase 4BB

View all 50 →

Same molecule, other indications

ZOPTARELIN DOXORUBICIN is also rated in:

endometrial carcinomaDormant
CC
Indicative ·
42 / 100
View asset →
breast cancerDormant
C
Indicative ·
39 / 100
View asset →
urothelial carcinomaDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →